Clinical trials: Invasive Candidiases
Candidemia
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
Prospective, open label study to assess the pharmacokinetics, safety \& efficacy of anidulafungin when used to treat children (aged 1 month - <18 years) with invasive candidiasis, including candidemia (ICC).
- Trial name
- NCT00761267
- Testing
- Anidulafungin, Fluconazole
- Where
- 45 sites in United States, Brazil and 8 more
- Volunteers
- 70 people
- Sponsor
- Pfizer
Invasive Candidiasis, Esophageal Candidiasis
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an antifungal drug. Safety and drug blood levels will be assessed
- Conditions
- Invasive Candidiasis, Esophageal Candidiasis, Oropharyngeal Candidiasis, Candidemia
- Trial name
- NCT00607763
- Testing
- Micafungin (Mycamine)
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Inc
Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Middle East Study of Infections in Patients With Hematological Malignancies
The goal of this prospective observational study is to is to prospectively study the epidemiology of bloodstream infection (BSI) in patients with hematological malignancies (HM) and hematopoietic stem cell transplant (HSCT)…
- Conditions
- Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Bloodstream Infection
- Trial name
- MESI-HM (NCT07900542)
- Testing
- No Intervention: Observational Cohort
- Where
- 9 sites in Jordan, Oman and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Hamad Medical Corporation
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Candidemia, Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV
The objective of this study is to collect the safety and efficacy data of Eraxis IV (anidulafungin) 100 mg according to Korea Ministry of Food and Drug Safety regulations.
- Trial name
- NCT00802854
- Where
- 10 sites in South Korea
- Volunteers
- 244 people
- Sponsor
- Pfizer
Candidiasis, Fungemia
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida
The purpose of this study is to gather information on the use of anidulafungin for the treatment of serious Candida infection. It is expected that anidulafungin will be at least as safe and as effective as the comparator drug…
- Trial name
- NCT00805740
- Testing
- Active anidulafungin, Active Caspofungin
- Where
- 18 sites in United States, Belgium and 7 more
- Volunteers
- 41 people
- Sponsor
- Pfizer
Aspergillosis, Candidemia
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.
- Trial name
- NCT00940017
- Testing
- anidulafungin and voriconazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Candidemia
Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)
The purpose of this study is to validate clinical performance (i.e. estimated sensitivity and specificity) of the T2 Candida test on the T2 DX Instrument compared to blood culture results and/or known Candida positive status of…
- Trial name
- direcT2 (NCT01752166)
- Where
- 8 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- T2 Biosystems
Patients With Candidemia and/or Invasive Candidiasis
A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis
The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS9432 in patients with candidemia and/or invasive candidiasis
- Trial name
- NCT06194201
- Testing
- HRS9432, Caspofungin Acetate for Injection
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Candidiasis
Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
Candida is the most common fungal pathogen identified in hospitalized patients. This study will seek to enroll adult patients (18 years of age or older) with invasive Candida infections (involving deep tissues and organs).
- Trial name
- NCT00083343
- Testing
- MK0991, caspofungin acetate/Duration of Treatment: variable
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidiasis, Invasive, Candidemia
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis including candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous…
- Trial name
- MARIO (NCT05178862)
- Testing
- SCY-078, Fluconazole, Echinocandin
- Where
- 101 sites in United States, Belgium and 11 more
- Volunteers
- 68 people
- Sponsor
- Scynexis, Inc.
Mycoses
A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects
Subjects with intra-abdominal infection requiring surgery and Intensive Care Unit stay will be treated early with micafungin or placebo to determine the incidence and time to confirmation of fungal infection.
- Trial name
- INTENSE (NCT01122368)
- Testing
- micafungin
- Where
- 56 sites in Austria, Belgium and 13 more
- Volunteers
- 252 people
- Sponsor
- Astellas Pharma Inc
Candidiasis, Invasive, Candidemia
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.
- Conditions
- Candidiasis, Invasive, Candidemia, Mycoses
- Trial name
- NCT00413218
- Testing
- Isavuconazole, Caspofungin, Voriconazole
- Where
- 113 sites in United States, Argentina and 23 more
- Volunteers
- 450 people
- Sponsor
- Astellas Pharma Inc
Candidiasis
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis
The study will evaluate how effective and how safe the drug micafungin is when compared to the drug amphotericin B deoxycholate in treating neonates and young infants with certain fungal infections.
- Trial name
- MAGIC-2 (NCT00815516)
- Testing
- micafungin, amphotericin B deoxycholate
- Where
- 17 sites in United States, Brazil and 10 more
- Volunteers
- 30 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Candidiasis
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or…
- Trial name
- NCT00106288
- Testing
- Micafungin, Liposomal Amphotericin B
- Where
- 37 sites in United States, Canada
- Volunteers
- 637 people
- Sponsor
- Astellas Pharma Inc
Invasive Candidiasis, Candidemia
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin…
- Trial name
- NCT01213823
- Testing
- Does not apply
- Volunteers
- 536 people, healthy volunteers welcome
- Sponsor
- Pfizer
Mycoses, Candidiasis, Invasive
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
The purpose of this study is to compare the safety, pharmacokinetics, and efficacy of oral SCY-078 vs. standard-of-care following initial intravenous echinocandin therapy in the treatment of invasive candidiasis.
- Conditions
- Mycoses, Candidiasis, Invasive, Candidemia
- Trial name
- NCT02244606
- Testing
- SCY-078, Fluconazole, Micafungin
- Where
- 30 sites in United States, El Salvador and 3 more
- Volunteers
- 27 people
- Sponsor
- Scynexis, Inc.
Candidemia
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
The purpose of this study is to assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Candida Assay.
- Trial name
- DIRECT (NCT01525095)
- Where
- 5 sites in United States
- Volunteers
- 700 people
- Sponsor
- T2 Biosystems
Candidiasis
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
The purpose of the study is to evaluate the safety and efficacy of FK463 in the treatment of patients with confirmed candidemia or invasive candidiasis.
- Trial name
- NCT00036179
- Testing
- FK463
- Where
- 23 sites in Austria, France and 6 more
- Volunteers
- 75 people
- Sponsor
- Astellas Pharma Inc
Candidiasis
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States…
- Trial name
- NCT00037219
- Testing
- Anidulafungin, VER002
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Pfizer